Compugen
Holon, Israel · Biotechnology, Biotechnology Research, Health Care
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class
Key facts
- Headquarters
- Holon, Israel
- Employees
- Unknown
- Industries
- Biotechnology, Biotechnology Research, Health Care
- Status
- Public (CGEN)
- Website
- cgen.com
- Company page
Recent activity at Compugen
- : C-Gen.AI raises $3.5 million in seed funding to enhance AI infrastructure and GPU utilization, emerging from stealth to revolutionize AI workloads.
- : Compugen Appoints Eran Ophir as President and Chief Executive Officer
- : Compugen Strengthens Defence + Security Industry with Strategic Acquisition of SynerSolutions
- : Compugen Inc. strengthens Defence + Security Industry with Strategic Acquisition of SynerSolutions Technologies Inc.
- : Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
- : Compugen Welcomes Kara Rudy as Vice President, Marketing
- : COMPUGEN LTD
- : COMPUGEN LTD
Compugen funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2025 | Seed | $3.5M |
| Nov 2021 | Venture | $20.0M |
| Oct 2018 | Venture | $12.0M |
Leadership
- Sanford Zweifach, Director
- Arie Ovadia, Director
- Kinneret Savitzky, Director
- Gilead Halevy, Director
- Jean-Pierre Bizzari, Director
- Yair Aharonowitz, Director
- Paul Sekhri, Director
- Anat Cohen-Dayag, Executive Officer, Director
- Eran Ophir, President
- Michelle Mahler, Chief Medical Officer
- Kara Rudy, Vice President of Marketing
- Zurit Levine, Executive Officer
Verified email and direct lines for Compugen’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Compugen files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Nov 2026.
Compugen in the news
- Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 - Yahoo Finance (Jul 20, 2026)
- Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress - Finansavisen (Jun 18, 2026)
- Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer - PR Newswire (Feb 15, 2024)
- Compugen (NasdaqCM:CGEN) Stock Price - Simply Wall Street (Jul 28, 2025)
- Compugen (CGEN) Stock Price, News & Analysis - MarketBeat (Jun 11, 2015)
- Compugen (Nasdaq:CGEN) - Stock Analysis - Simply Wall Street (Dec 02, 2017)
Companies similar to Compugen
- Strata Oncology · Biotechnology, Health Care, Medical, Other, Therapeutics
- Corcept · Biotechnology, Biotechnology Research, Health Care, Medical, Therapeutics
- Neumora · Biotechnology, Biotechnology Research, Health Care, Therapeutics
- Navion Neurosciences · Biotechnology, Health Care, Medical, Therapeutics
- Acrivon Therapeutics · Biotechnology, Health Care, Medical, Therapeutics
About Compugen: questions and answers
What does Compugen do?
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class
Where is Compugen headquartered?
Compugen is headquartered in Holon, Israel.
Has Compugen raised funding?
Yes. Fundz has recorded 3 funding events for Compugen. The most recent, Seed of $3.5M, was in Jul 2025.
Who leads Compugen?
Eran Ophir is a President at Compugen.
What is the latest news on Compugen?
On Jul 15, 2025, C-Gen.AI raises $3.5 million in seed funding to enhance AI infrastructure and GPU utilization, emerging from stealth to revolutionize AI workloads.
Is Compugen a public company?
Yes. Compugen is publicly traded under the ticker CGEN.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy